FDA Clearance Tracker · P850048-S021
ACCESS HYBRITECH PSA WHO STANDARDIZATION
Last checked: Nov 20, 2026Latest source record: May 9, 2008 (this decision)Source: openFDAMethods & limitations
Decided
May 9, 2008
Approved
Time to decision
262 days
Received Aug 21, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P850048-S021
- Device name
- ACCESS HYBRITECH PSA WHO STANDARDIZATION
- Applicant
- Beckman Coulter, Inc.
- Applicant location
- Brea, CA
- Received
- Aug 21, 2007
- Decided
- May 9, 2008
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P850048
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ACCESS HYBRITECH PSA REAGENTS ON THE ACCESS IMMUNOASSAY SYSTEMS. THE ACCESS HYBRITECH PSA ASSAY IS A PARAMAGNETIC PARTICLE, CHEMILUMINESCENT IMMUNOASSAY FOR THE QUANTITATIVE DETERMINATION OF TOTAL PROSTATE SPECIFIC ANTIGEN (PSA) IN HUMAN SERUM USING THE ACCESS IMMUNOASSAY SYSTEMS. THE DEVICE IS INDICATED FOR THE MEASUREMENT OF SERUM PSA IN CONJUNCTION WITH DIGITAL RECTAL EXAMINATION (DRE) AS AN AID IN THE DETECTION OF PROSTATE CANCER IN MEN AGED 50 YEARS OR OLDER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF CANCER. THE DEVICE IS FURTHER INDICATED FOR THE SERIAL MEASUREMENT OF PSA TO AID IN THE PROGNOSIS AND MANAGEMENT OF PATIENTS WITH PROSTATE CANCER.
Source documents
Other decisions for Beckman Coulter, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Access BNP II510(k)
K262597 · Decided Oct 20, 2026 · 85 days after receipt
Device type: Test, Natriuretic Peptide (NBC) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.